HER2 positivity as a predictor of brain metastases in breast cancer: A systematic literature review
DOI: https://doi.org/10.33024/minh.v8i8.1159
Brain Metastasis Breast Cancer HER2-Positive Predictive Factor Systematic Review
Abstract
Background: Breast cancer remains one of the most prevalent and lethal malignancies among women globally, which leads to the critical importance of early detection and a more comprehensive approach to breast cancer management.
Purpose: To investigate HER2 positivity as a predictor of brain metastases in breast cancer.
Methods: A total of 23 peer-reviewed studies published between 2015 and 2025 were analyzed, including randomized trials, retrospective cohorts, prediction model studies, and registry-based evaluations. Eligibility was guided by the PICOTS framework, and databases searched included PubMed, Scopus, MDPI, Elsevier, SagePub, and BMC Cancer.
Results: The review confirms that HER2 overexpression significantly correlates with earlier brain metastasis onset, increased incidence, and distinctive treatment response profiles. HER2 status also influences survival outcomes and benefits from targeted agents such as trastuzumab, tucatinib, and pyrotinib. HER2-low expression additionally showed intermediate risk profiles, while imaging and circulating tumor cell data added prognostic value.
Conclusion: HER2 positivity is a robust, independent predictor of brain metastasis in breast cancer patients. Routine integration of HER2 profiling in CNS risk assessment models may improve early detection and therapeutic precision, ultimately enhancing clinical outcomes for high-risk populations.
Downloads
References
Avila, J., Leone, J., Vallejo, C. T., Lin, N. U., & Leone, J. P. (2024). Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade. Breast Cancer Research and Treatment, 205(3), 579–587.
Bryan, S., Witzel, I., Borgmann, K., & Oliveira-Ferrer, L. (2021). Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers. Cancers, 13(16), Article 16.
Cacho-Díaz, B., Valdés-Ferrer, S. I., Chavez-MacGregor, M., Salmerón-Moreno, K., Villarreal-Garza, C., & Reynoso-Noverón, N. (2024). Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer. Radiotherapy and Oncology, 197, 110379.
Cao, W., Qin, K., Li, F., & Chen, W. (2024). Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). Journal of the National Cancer Center, 4(2), 128–134.
Dai, L., Gao, T., Guo, R., Chen, Y., Wang, J., Zhou, S., Tang, Y., Chen, D., & Huang, S. (2024). Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study. Neoplasia, 56, 101029.
Erickson, A. W., Ghodrati, F., Habbous, S., Jerzak, K. J., Sahgal, A., Ahluwalia, M. S., & Das, S. (2020). HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: A systematic review and meta-analysis. Neuro-Oncology Advances, 2(1), vdaa136.
Filho, A. M., Laversanne, M., Ferlay, J., Colombet, M., Piñeros, M., Znaor, A., Parkin, D. M., Soerjomataram, I., & Bray, F. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. International Journal of Cancer, 156(7), 1336–1346.
Frenel, J.-S., Zeghondy, J., Guérin-Charbonnel, C., Mailliez, A., Volant, E., Poumeaud, F., Patsouris, A., Arnedos, M., Bailleux, C., Cabal, J., Galland, L., De Nonneville, A., Guiu, S., Dalenc, F., Pistilli, B., Bachelot, T., Pierga, J.-Y., Le Du, F., Bocquet, F., & Loirat, D. (2024). Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients with ERBB2 -Positive Metastatic Breast Cancer. JAMA Network Open, 7(4), e244435.
Guven, D. C., Kaya, M. B., Fedai, B., Ozden, M., Yildirim, H. C., Kosemehmetoglu, K., Kertmen, N., Dizdar, O., Uner, A., & Aksoy, S. (2022). HER2-low breast cancer could be associated with an increased risk of brain metastasis. International Journal of Clinical Oncology, 27(2), 332–339.
Hackshaw, M. D., Danysh, H. E., Henderson, M., Wang, E., Tu, N., Islam, Z., Ladner, A., Ritchey, M. E., & Salas, M. (2021). Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: A systematic literature review. BMC Cancer, 21(1), 967.
Kaplan, M. A., Ertugrul, H., Firat, U., Kucukoner, M., İnal, A., Urakci, Z., Pekkolay, Z., & Isikdogan, A. (2015). Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer, 22(5), 503–509.
Kaufman, P. A., Neuberger, E., Schwartz, N. R. M., Wang, S., Liu, Y., Hsu, L.-I., Bartley, K., Blahna, M. T., Pittner, B. T., Wong, G., & Anders, C. (2023). Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer. Frontiers in Oncology, 13, 1264861.
Lin, N. U., Murthy, R. K., Abramson, V., Anders, C., Bachelot, T., Bedard, P. L., Borges, V., Cameron, D., Carey, L. A., Chien, A. J., Curigliano, G., DiGiovanna, M. P., Gelmon, K., Hortobagyi, G., Hurvitz, S. A., Krop, I., Loi, S., Loibl, S., Mueller, V., & Winer, E. (2023). Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients with Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncology, 9(2), 197.
Lu, Y., Huang, Y., Zhu, C., Li, Z., Zhang, B., Sheng, H., Li, H., Liu, X., Xu, Z., Wen, Y., Zhang, J., & Zhang, L. (2025). Cancer brain metastasis: Molecular mechanisms and therapeutic strategies. Molecular Biomedicine, 6(1), 12.
Rashid, N. S., Lamba, N., Catalano, P. J., Bi, W. L., Arnaout, O., Tanguturi, S. K., Rahman, R., Haas-Kogan, D. A., Lin, N. U., Wen, P. Y., & Aizer, A. A. (2025). Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes. Breast Cancer Research and Treatment, 209(2), 303–314.
Sachar, S., Chen, E., Harris, E. E., Montero, A. J., & Choi, S. (2022). Impact of Hormone Receptor Status on Development of Brain Metastases from HER2+ Breast Cancer. International Journal of Radiation Oncology-Biology-Physics, 114(3), e62–e63.
Sacks, P., & Rahman, M. (2020). Epidemiology of Brain Metastases. Neurosurgery Clinics, 31(4), 481–488.
Terry, F., Orrego-Gonzalez, E., Enríquez-Marulanda, A., Pacheco-Barrios, N., Merenzon, M., Komotar, R. J., & Vega, R. A. (2025). Temporal Dynamics and Clinical Predictors of Brain Metastasis in Breast Cancer: A Two-Decade Cohort Analysis Toward Tailored CNS Screening. Cancers, 17(6), 946.
Trifănescu, O. G., Mitrea, D., Galeș, L. N., Ciornei, A., Păun, M.-A., Butnariu, I., Trifănescu, R. A., Motaș, N., Toma, R. V., Bîlteanu, L., Gherghe, M., & Anghel, R. M. (2023). Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New Treatment Options Can Improve Oncologic Outcomes in Leptomeningeal Metastases from HER2-Positive Breast Cancer. Cancers, 15(9), 2508.
Tung, I., Moldovan, C., Wong, V., De Boer, R., Yeo, B., Malik, L., Greenberg, S., Anton, A., Nott, L., Barnett, F., Collins, I. M., Lombard, J., Nottage, M., Sahu, A., Torres, J., Gibbs, P., & Lok, S. W. (2022). Real-World Outcomes in Patients with Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study. Clinical Breast Cancer, 22(7), e764–e772.
Vaz Batista, M., Pérez-García, J. M., Garrigós, L., García-Sáenz, J. Á., Cortez, P., Racca, F., Blanch, S., Ruiz-Borrego, M., Fernández-Ortega, A., Fernández-Abad, M., Iranzo, V., Gion, M., Martrat, G., Alcalá-López, D., Pérez-Escuredo, J., Sampayo-Cordero, M., Llombart-Cussac, A., Braga, S., & Cortés, J. (2025). The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med, 6(1), 100502.
Wanda, D., Sandhika, W., Sandhika, W., & Sandhika, W. (2024). VDR and WNT/β-catenin Expression in Invasive Breast Carcinoma of No Special Type: Role and Prognostic Value. Pharmacognosy Journal, 16(6), 1349–1354.
Wu, Q., Sun, M.-S., Liu, Y.-H., Ye, J.-M., & Xu, L. (2023). Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 149(13), 12333–12353.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sakinah Mar'ie Sanad, I Made Oka Adnyana, I Putu Eka Widyadharma
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
